Apoptosis
Apoptosis, also known as programmed cell death, is rigorously controlled process of cell death that leads to phagocytosis of unwanted cell. It is triggered after sufficient cellular damage and activated through extrinsic or intrinsic pathways. The intrinsic pathway is mainly occurs via release of cytochrome c from the mitochondria and regulates mitochondrial outer membrane permeabilization by Bcl-2 family proteins. The extrinsic pathway is induced by ligand binding to death receptor, such as Fas, TNFαR, DR3, DR4, and DR5. Caspases then cleave target proteins and nuclear lamins to promote DNA degradation, resulting apoptotic cells undergo phagocytosis. In addition, p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some Inhibitors of apoptosis proteins (IAPs), such as XIAP/BIRC4 and Bruce/BIRC6, can block casapse activity through direct binding, while other IAPs, such as cIAP1/BIRC2, cIAP2/BIRC3, act as ubiquitin ligases that target caspases for ubiquitin-mediated degradation. Apoptosis is essential for growth, development and aging in multicellular organisms. Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases, including cancer.
-
BA3162 NVX-207Summary: NVX-207 is a Betulinicacid-derived anticancer compound. - BA3163 Thalidomide-NH-C6-NH-BocSummary: Thalidomide-NH-C6-NH-Boc is a synthetic E3 ligase ligand-ligand protein coupling compound combining ligand-based Thalidomide and ligand proteins for the synthesis of MI-389 (Compound 22).
- BA3165 GGTI298Summary: GGTI298 is a potent GGTaseI inhibitor.
- BA3166 Thalidomide-O-amido-C3-PEG3-C1-NH2Summary: Thalidomide-O-amido-C3-PEG3-C1-NH2 is a synthetic E3 ligase ligand-linker coupler.
- BA3167 CMLD010509Summary: CMLD010509 (SDS-1-021) is a highly specific inhibitor that supports the oncogenic translational program in multiple myeloma (MM).
- BA3168 NevanimibeSummary: Nevanimibe (PD-132301) is an orally effective, selective acyl coenzyme A:cholesterol O-acyltransferase 1 inhibitor.
- BA3169 S2116Summary: S2116, an N-alkylated trans-cyclopropylamine (TCP) derivative, is a potent lysine-specific demethylase 1 inhibitor.
- BA3170 CantrixilSummary: Cantrixil (TRX-E-002-1) is the active enantiomer of TRX-E-002, a second generation superbenzopyran (SBP) compound.
- BA3171 S2157Summary: S2157, an N-alkylated trans-cyclopropylamine (TCP) derivative, is a potent lysine-specific demethylase 1 inhibitor.
- BA3172 Thalidomide-piperazine-BocSummary: An intermediate that can be used in the synthesis of BCL6.